William Novotny

William Novotny

UNVERIFIED PROFILE

Are you William Novotny?   Register this Author

Register author
William Novotny

William Novotny

Publications by authors named "William Novotny"

Are you William Novotny?   Register this Author

25Publications

970Reads

15Profile Views

Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study.

Leukemia 2019 Sep 13. Epub 2019 Sep 13.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0545-2DOI Listing
September 2019

Mechanical ventilation for a child with quadriplegia.

Pediatrics 2014 Sep;134(3):593-7

University of Missouri at Kansas City and Children's Mercy Hospital, Kansas City, Missouri

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1542/peds.2013-4161DOI Listing
September 2014

Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.

J Clin Oncol 2010 Jun 10;28(17):2839-46. Epub 2010 May 10.

University of Texas M D Anderson Cancer Center, Thoracic Head and Neck Medicine Clinic, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.25.1991DOI Listing
June 2010

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

Cancer Chemother Pharmacol 2008 Oct 19;62(5):779-86. Epub 2008 Jan 19.

Department of Pharmacokinetic and Pharmacodynamic Sciences, Genentech, Inc., 1 DNA Way, MS70, South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-007-0664-8DOI Listing
October 2008

An 18-yr prospective study of pediatric diabetic ketoacidosis: an approach to minimizing the risk of brain herniation during treatment.

Pediatr Diabetes 2007 Jun;8(3):142-9

Section of Pediatric Critical Care, Department of Pediatrics, Brody School of Medicine at East Carolina University, Greenville, NC 27834, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1399-5448.2007.00253.x
Publisher Site
http://dx.doi.org/10.1111/j.1399-5448.2007.00253.xDOI Listing
June 2007

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.

Biochem Biophys Res Commun 2005 Jul;333(2):328-35

Department of Molecular Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S0006291X0501134
Publisher Site
http://dx.doi.org/10.1016/j.bbrc.2005.05.132DOI Listing
July 2005

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

J Clin Oncol 2005 Jun 28;23(16):3697-705. Epub 2005 Feb 28.

Division of Hematology/Oncology, UCLA School of Medicine, 10945 LeConte Ave, Suite 2338J, Los Angeles, CA 90095-7187, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.05.112DOI Listing
June 2005

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.

J Clin Oncol 2005 May;23(15):3502-8

Department of Medical Oncology and Transplantation, Room 25132, Morris Building, Box 3052, Duke University Medical Center, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.10.017DOI Listing
May 2005

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.

Nat Rev Drug Discov 2004 May;3(5):391-400

Department of Molecular Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd1381DOI Listing
May 2004

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.

Semin Oncol 2003 Oct;30(5 Suppl 16):117-24

Rush-Presbyterian-St Lukes Medical Center, Chicago, IL 60612, USA.

View Article

Download full-text PDF

Source
October 2003

Faith-based decisions: parents who refuse appropriate care for their children.

Virtual Mentor 2003 Aug 1;5(8). Epub 2003 Aug 1.

Clinical ethics at the Center for Bioethics and Human Dignity, in Bannockburn, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/virtualmentor.2003.5.8.ccas1-0308DOI Listing
August 2003

Continuous venovenous hemodiafiltration in hypernatremic hyperglycemic nonketotic coma.

Pediatr Nephrol 2002 Nov 16;17(11):969-73. Epub 2002 Aug 16.

Division of Nephrology, Department of Pediatrics, Brody School of Medicine, East Carolina University, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00467-002-0947-6DOI Listing
November 2002

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

J Clin Oncol 2002 Feb;20(3):719-26

University of Miami School of Medicine, Comprehensive Cancer Research Group Inc, and Columbia Cancer Research Network of Florida, Miami, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2002.20.3.719DOI Listing
February 2002